Vaginal Cancer: H1 2018 Pipeline Review - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

DUBLIN--()--The "Vaginal Cancer - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Vaginal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 6, 1 and 1 respectively.

Companies Mentioned

  • Bristol-Myers Squibb Co
  • Fujifilm Holdings Corporation
  • ISA Pharmaceuticals BV
  • MedImmune LLC
  • Merck KGaA
  • Ology Bioservices Inc
  • Ono Pharmaceutical Co Ltd
  • Transgene SA

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Vaginal Cancer - Overview
  4. Vaginal Cancer - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Vaginal Cancer - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Vaginal Cancer - Companies Involved in Therapeutics Development
  14. Bristol-Myers Squibb Co
  15. Fujifilm Holdings Corporation
  16. ISA Pharmaceuticals BV
  17. MedImmune LLC
  18. Merck KGaA
  19. Ology Bioservices Inc
  20. Ono Pharmaceutical Co Ltd
  21. Transgene SA
  22. Vaginal Cancer - Drug Profiles
  23. durvalumab + tremelimumab - Drug Profile
  24. Product Description
  25. Mechanism Of Action
  26. R&D Progress
  27. FF-21101 - Drug Profile
  28. Product Description
  29. Mechanism Of Action
  30. R&D Progress
  31. ipilimumab + nivolumab - Drug Profile
  32. Product Description
  33. Mechanism Of Action
  34. R&D Progress
  35. ISA-101 - Drug Profile
  36. Product Description
  37. Mechanism Of Action
  38. R&D Progress
  39. M-7824 - Drug Profile
  40. Product Description
  41. Mechanism Of Action
  42. R&D Progress
  43. nivolumab - Drug Profile
  44. Mechanism Of Action
  45. R&D Progress
  46. NTO-1151 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. TG-4001 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. Vaginal Cancer - Dormant Projects
  55. Appendix
  56. Methodology
  57. Coverage
  58. Secondary Research
  59. Primary Research
  60. Expert Panel Validation

For more information about this report visit https://www.researchandmarkets.com/research/br85mp/vaginal_cancer?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Cervical Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Women's Health, Cervical Cancer Drugs